Piramal settles desflurane litigation with Baxter, set to begin US manufacture in 2012
This article was originally published in Scrip
Piramal Critical Care, part of India's Piramal group, can manufacture desflurane, a generic version of Baxter's Suprane inhaled anaesthetic agent, in the US next year as part of a patent litigation settlement for the product.
You may also be interested in...
Peter DeYoung, CEO of Piramal Critical Care, expects to build “profitable growth positions” from the injectable products acquired from Janssen. He is also upbeat about the commercialization prospects in Europe for intrathecal baclofen and the potential launch of the first desflurane generic in the US.
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.